If Goldseeker is trying to drive down the price, he is certainly succeeding. As for me, although the drop in price makes me more nervous, I'm still in because:
1. BOCX researched and developed the RECAF biomarker just as they said they would, and so far, no one has had anything bad to say about it.
2. Their Scientific Advisory board is a "who's who" of cancer marker researchers. These guys are cream of the crop internationally! Could they have been duped into joining BOCX's SAB? Possibly, but not very likely. They must have seen promise in the technology.
3. BOCX developed the radio-immunoassay RECAF test and achieved excellent results, just as they said they would.
4. BOCX licensed RECAF technology to a major company (Abbott), just as they said they would.
5. BOCX developed a colorimetric test to make the RECAF technology more marketable, just as they said they would. Now they're in the process of tweaking it to get the results as close to the radio-immunoassay results as possible.
6. BOCX has now signed a collaboration agreement with a reknown Russian cancer hospital to try out the RECAF test in a real-world environment. This should help them figure out how to best use the RECAF test results.
7. If the underlying RECAF technology is sound, they still have huge imaging and therapuetics applications that can be pursued. developed.
AI
